title: Chronic myeloid leukemia lysate-loaded dendritic cells induce T-cell responses towards leukemia progenitor cells.
abstract: Treatment of chronic myeloid leukemia with tyrosine kinase inhibitors, such as imatinib mesylate, dasatinib and nilotinib, results in high rates of cytogenetic and molecular responses. However, in many patients, minimal residual disease is detected by molecular techniques. Since chronic myeloid leukemia cells are particularly good targets for immune surveillance mechanisms, we explored active specific immunotherapy using leukemia lysate-loaded dendritic cells in vitro. Our data show the potency of dendritic cell-based vaccination strategies for the induction of T cell-mediated responses to eradicate minimal residual disease.
authors.affiliation: Department of Hematology, Cancer Center Amsterdam/VUmc Institute for Cancer & Immunology, VU University Medical Center, Amsterdam, The Netherlands. tm.westers@vumc.nl
authors.forename: Theresia M
authors.initials: TM
authors.lastname: Westers
authors.forename: Willemijn
authors.initials: W
authors.lastname: van den Ancker
authors.forename: Hetty J
authors.initials: HJ
authors.lastname: Bontkes
authors.forename: Jeroen J W M
authors.initials: JJ
authors.lastname: Janssen
authors.forename: Arjan A
authors.initials: AA
authors.lastname: van de Loosdrecht
authors.forename: Gert J
authors.initials: GJ
authors.lastname: Ossenkoppele
mesh_terms: D019496:Cancer Vaccines / Q000008:administration & dosage / Q000276:immunology*; D018920:Coculture Techniques; D003713:Dendritic Cells / Q000166:cytology / Q000276:immunology*; D006801:Humans; D016233:Immunotherapy, Active / Q000379:methods*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000276:immunology* / Q000628:therapy; D008213:Lymphocyte Activation; D009000:Monocytes / Q000166:cytology; D018365:Neoplasm, Residual / Q000276:immunology / Q000628:therapy; D014411:Neoplastic Stem Cells / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology*
chemical_list: D019496:Cancer Vaccines